Date Time
Examining resistance to breast cancer treatments
The combination of CDK4/6 inhibitors with endocrine therapy is the standard of care for patients with estrogen receptor-positive (ER+) and HER2-negative (ER+/HER2-) metastatic breast cancer. However, a subset of patients will have tumors with intrinsic resistance to this therapy and most patients will develop resistant disease at some point during treatment.
Researchers at the Lester and Sue Smith Breast Center and the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine examined gene expression data from preclinical models of ER+ breast cancer and from patients with early ER+/HER2- breast cancer who were participating in neoadjuvant trials of CDK4/6 inhibitors and found an association between high interferon (IFN) signaling and resistance to the treatment. The findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research, may aid in helping doctors identify whi